IDH1 and neoplasm: In gliomas, hBCATm has been identified as a negative prognostic marker in IDH1-WT gliomas [18], supporting the hypothesis for hBCATm to contribute to tumour progression in the absence of IDH mutation, which is a rare event in breast cancer [32, 33].